As mentioned in the previous part, the immunogenicity of breast cancer varies among multiple molecular variants, with TNBC and HER2+ tumors being more immunogenic, while luminal A and luminal B subtypes are less immunogenic.119 Since breast cancer is a highly heterogeneous disorder, it is not surprising that the subtype changes metastasis or under the pressure of therapies.122 Neoadjuvant chemotherapy can probably change ER and PR expression and status. Here, ERBB2 is linked to breast cancer.